In this article, we will review incretin physiology and evidence supporting a role of GLP-1 in the pathophysiology of hyperinsulinemic hypoglycemia, as well as results from proof-of concept studies exploring a therapeutic approach targeting the GLP-1 receptor to treat hyperinsulinemic hypoglycemia. The gene discussed is GCG; the disease is hyperinsulinemic hypoglycemia.